Rivastigmine tartrate

Details:

Melting point     123-1250C
alpha     D20 +4.7° (c = 5 in ethanol)
storage temp.     2-8°C
solubility     H2O: soluble15mg/mL, clear
form     powder
color     white to beige
CAS DataBase Reference    129101-54-8(CAS DataBase Reference)
Safety Information
RIDADR     UN 2811 6.1 / PGII
WGK Germany     3
RTECS     FA9550000
HazardClass     6.1
PackingGroup     III
HS Code     29242990

Pharmacological effects    Rivastigmine tartrate is rivastigmine Alzheimer's disease drugs, rivastigmine is physostigmine derivative by Novartis for the first time successfully developed the trade name Exelon (exelon), a molecule with there carbamate structure, is a kind of amino acid of selective cerebral cholinesterase inhibitor, can also inhibit the acetylcholinesterase and butyrylcholinesterase, cholinergic neurons by delaying the release of acetylcholine degradation and energy promoting cholinergic nerve conduction, can improve cognitive function disorders mediated by cholinergic, thereby improving the cognitive function of Alzheimer's disease patients. Rivastigmine plasma protein binding is weak, easily through the blood-brain barrier, which has a high degree of brain selectivity. It not only selectively acts on the most easily affected cerebral cortex and hippocampus, but also preferentially inhibits the dominant subtype of AChE in the brain, resulting in a reduction in the efficacy of peripheral cholinergic side effects. Rivastigmine in vivo half-life is short and long duration of action. Unlike tacrine, this product in the hippocampus and cortex of G1 enzyme inhibitory effect is stronger. Clinic for the treatment of mild to moderate Alzheimer-type dementia, or Alzheimer's disease can be suspected Alzheimer's disease clinically.